CA3164055A1 - Cellules modifiees et methodes pour le traitement d'hemoglobinopathies - Google Patents

Cellules modifiees et methodes pour le traitement d'hemoglobinopathies

Info

Publication number
CA3164055A1
CA3164055A1 CA3164055A CA3164055A CA3164055A1 CA 3164055 A1 CA3164055 A1 CA 3164055A1 CA 3164055 A CA3164055 A CA 3164055A CA 3164055 A CA3164055 A CA 3164055A CA 3164055 A1 CA3164055 A1 CA 3164055A1
Authority
CA
Canada
Prior art keywords
cells
population
modified
hbg1
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164055A
Other languages
English (en)
Inventor
Jennifer Leah GORI
Edouard AUPEPIN DE LAMOTHE-DREUZY
Jack HEATH
John Anthony Zuris
KaiHsin CHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Editas Medicine Inc
Original Assignee
Editas Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc filed Critical Editas Medicine Inc
Priority claimed from PCT/US2020/063854 external-priority patent/WO2021119040A1/fr
Publication of CA3164055A1 publication Critical patent/CA3164055A1/fr
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des systèmes d'édition du génome, des ARN guides et des procédés à médiation par CRISPR pour modifier des parties des loci des gènes HBG1 et HBG2 dans des cellules et augmenter l'expression de l'hémoglobine ftale.
CA3164055A 2019-12-08 2020-12-09 Cellules modifiees et methodes pour le traitement d'hemoglobinopathies Pending CA3164055A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62/945,190 2019-12-08
US202063115518P 2020-11-18 2020-11-18
US63/115,518 2020-11-18
PCT/US2020/063854 WO2021119040A1 (fr) 2019-12-08 2020-12-09 Cellules modifiées et méthodes pour le traitement d'hémoglobinopathies

Publications (1)

Publication Number Publication Date
CA3164055A1 true CA3164055A1 (fr) 2021-06-17

Family

ID=82309508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164055A Pending CA3164055A1 (fr) 2019-12-08 2020-12-09 Cellules modifiees et methodes pour le traitement d'hemoglobinopathies

Country Status (3)

Country Link
JP (1) JP2023521524A (fr)
CN (1) CN115175990A (fr)
CA (1) CA3164055A1 (fr)

Also Published As

Publication number Publication date
JP2023521524A (ja) 2023-05-25
CN115175990A (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
US12031132B2 (en) Systems and methods for the treatment of hemoglobinopathies
US11963982B2 (en) CRISPR/RNA-guided nuclease systems and methods
US11851690B2 (en) Systems and methods for the treatment of hemoglobinopathies
US20240191197A1 (en) Modified cells and methods for the treatment of hemoglobinopathies
US20220073951A1 (en) Systems and methods for the treatment of hemoglobinopathies
US20210230638A1 (en) Systems and methods for the treatment of hemoglobinopathies
US20220047637A1 (en) Systems and methods for the treatment of hemoglobinopathies
US20200263206A1 (en) Targeted integration systems and methods for the treatment of hemoglobinopathies
EP3701028B1 (fr) Systèmes et méthodes de traitement du syndrome d'hyper-igm
US20240335476A1 (en) Systems and methods for the treatment of hemoglobinopathies
CA3164055A1 (fr) Cellules modifiees et methodes pour le traitement d'hemoglobinopathies
US20220025363A1 (en) Systems and methods for the treatment of hemoglobinopathies
WO2024123842A1 (fr) Systèmes et méthodes pour le traitement d'hémoglobinopathies
CN117940566A (zh) 用于治疗血红蛋白病的系统和方法